Asia-Pacific healthcare management group HealthMutual Group and private oncology provider OncoCare have formalised a strategic partnership to create an integrated pan-Asian oncology care network spanning Singapore, Hong Kong, and Malaysia.

According to a report by Macau Business, the two organisations signed a Pan-Asian Strategic Cooperation Agreement, building on a memorandum of understanding signed last November. The agreement expands the scope of the original arrangement beyond local medical services in Hong Kong to enable HealthMutual Group's clients to access OncoCare's oncology teams and professional nursing services across the broader Pan-Asian region.

HealthMutual Group serves more than 700,000 clients of its insurance partners across Asia-Pacific and processed total medical expenses exceeding HKD150 million (€17.4 million) in 2025 alone. The group has built an extensive multinational medical network across the region, with a focus on optimising medical administration and claims processes through digital transformation.

OncoCare, a subsidiary of integrated oncology group Tamarind Health, operates flagship centres in Central and Tsim Sha Tsui in Hong Kong, a Singapore headquarters, and a Malaysia branch. Its clinical model brings together oncologists and specialists across colorectal surgery, cardiothoracic surgery, breast surgery, respiratory medicine, and family medicine, offering cross-disciplinary assessments, precision cancer treatment plans, and personalised care.

The core of the agreement is the establishment of what both parties describe as Asia's premier Pan-Asian Closed-Loop Medical Ecosystem, with Singapore, Hong Kong, and Malaysia serving as hub locations. Key elements include cross-border multidisciplinary team diagnosis drawing on specialists from all three markets, integrated financial settlement and transparent medical billing, and seamless connectivity between HMG's client network and OncoCare's clinical teams.

The partnership introduces a full-cycle, one-stop care model spanning early screening, multidisciplinary diagnosis, cross-border referrals, and personalised treatment plans for common cancers, with clear financial predictability built into the offering for patients and their families.

For private healthcare operators and insurers active across Asia-Pacific, the agreement illustrates a growing trend towards integrated cross-border oncology networks that combine clinical expertise, administrative infrastructure, and financial transparency within a single managed ecosystem, addressing the complexity and cost uncertainty that has historically complicated cancer care delivery across multiple Asian markets.